DAREON™-9: A Study to Test How Well Different Doses of BI 764532 Are Tolerated by People With Small Cell Lung Cancer When Taken Together With a Single Agent Chemotherapy
Condition: Small Cell Lung Carcinoma (SCLC) · Sponsor: Boehringer Ingelheim
About this study
This study is open to adults with extensive stage small cell lung cancer. The study is in people with advanced cancer that had previously received platinum-based chemotherapy and are eligible to receive a single agent chemotherapy treatment. The purpose of this study is to find the highest dose of BI 764532 that people can tolerate when taken together with a single agent chemotherapy. BI 764532 is an antibody-like molecule that may help the immune system fight cancer. Participants may continue to take BI 764532 as long as they benefit from treatment and can tolerate it. During this time, participants visit the study site regularly. The visits also depend on the response to the treatment. At the study visits, the doctors check the health of the participants, take necessary laboratory tests, and note any health problems that could have been caused by the study treatment.
This description comes directly from the study's public registry record.
Talk to the study team
No contact information is available for this study as per the public registry record.
Always discuss trial participation with your own doctor first.
Locations (14)
| MedStar Georgetown University Hospital | Washington D.C., District of Columbia, United States | — |
| Mayo Clinic - Florida | Jacksonville, Florida, United States | — |
| University of Miami | Miami, Florida, United States | — |
| Virginia Commonwealth University | Richmond, Virginia, United States | — |
| INS Curie | Paris, France | — |
| HOP Civil | Strasbourg, France | — |
| Institut Gustave Roussy | Villejuif, France | — |
| Universitätsklinikum Carl Gustav Carus Dresden | Dresden, Germany | — |
| Universitätsklinikum Erlangen | Erlangen, Germany | — |
| Thoraxklinik-Heidelberg gGmbH am Universitätsklinikum Heidelberg | Heidelberg, Germany | — |
| Universitätsmedizin der Johannes Gutenberg-Universität Mainz | Mainz, Germany | — |
| Universitätsklinikum Würzburg AÖR | Würzburg, Germany | — |
+ 2 more locations — full list on the registry record.
Follow this study
Save your interest here for when the public record changes — results posted, or the study's status changes. Email alerts for this study aren't switched on yet.
We keep this only about this public record, and never email you without alerts being switched on. Want it removed at any time? Email hello@eichor.com. Never medical advice. By subscribing you agree to our Terms of Use and Privacy Policy.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05990738